Evidence map›Paper›PMID 25572032›Full record

Trial reportBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2015

ABO mismatch is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation.

Aaron C Logan, Zhiyu Wang, Kamran Alimoghaddam, Ruby M Wong, Tze Lai, Robert S Negrin, Carl Grumet, Brent R Logan, Mei-Jie Zhang, Stephen R Spellman and 3 more

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. [ABO incompatibility and complications in hematopoietic stem cell transplantation].Revista medica del Instituto Mexicano del Seguro Social · 2023
    Observational
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Peritransplantation Red Blood Cell Transfusion Is Associated with Increased Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Aaron C LoganDivision of Hematology and Blood and Marrow Transplantation, Department of Medicine, University of California, San Francisco, San Francisco, California.
Zhiyu WangHealth Research and Policy, Stanford University School of Medicine, Stanford, California.
Kamran AlimoghaddamHematology, Oncology, and Stem Cell Transplantation, Tehran University of Medical Sciences, Tehran, Iran.
Ruby M WongHealth Research and Policy, Stanford University School of Medicine, Stanford, California.
Tze LaiHealth Research and Policy, Stanford University School of Medicine, Stanford, California.
Robert S NegrinDivision of Blood and Marrow Transplantation, Department of Medicine, Stanford University School of Medicine, Stanford, California.
Carl GrumetDepartment of Pathology, Stanford University School of Medicine, Stanford, California.
Brent R LoganDivision of Biostatistics, Medical College of Wisconsin, Milwaukee, Wisconsin.
Mei-Jie ZhangDivision of Biostatistics, Medical College of Wisconsin, Milwaukee, Wisconsin.
Stephen R SpellmanCenter for International Blood and Marrow Transplant Research, Minneapolis, Minnesota.
Stephanie J LeeFred Hutchinson Cancer Center, Seattle, Washington.
David B MiklosDivision of Blood and Marrow Transplantation, Department of Medicine, Stanford University School of Medicine, Stanford, California. Electronic address: dmiklos@stanford.edu.
Center for International Blood and Marrow Transplantation

Funding

Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
TUMOR SPECIFIC CYTOTOXIC T-LYMPHOCYTES IN BONE MARROW TRANSPLANTATIONP01CA049605 · NCI · STANFORD UNIVERSITY · PI David B. Miklos · 1989 to 2026
$73.3M
Easy-to-read Informed Consent for HCT Clinical TrialsU10HL069294 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI HOROWITZ, MARY MARESCA · 2011 to 2016
$43.8M
NCI NIH HHS P01 CA049605NCI NIH HHS P01CA049605NCI NIH HHS U24 CA076518NCI NIH HHS U24-CA076518NHLBI NIH HHS 5U10HL069294NHLBI NIH HHS U10 HL069294
6 · The paper itself

Abstract

We evaluated ABO associated outcomes in 1737 patients who underwent allogeneic hematopoietic cell transplantation (allo-HCT) at Stanford University between January 1986 and July 2011. Grafts were 61% ABO matched, 18% major mismatched (MM), 17% minor MM, and 4% bidirectional MM. Median follow-up was 6 years. In multivariate analysis, overall survival (OS) was inferior in minor MM hematopoietic cell transplantations (median 2.1 versus 6.3 years; hazard ratio [HR], 1.56; 95% confidence interval [CI], 1.19 to 2.05; P = .001) in comparison with ABO-matched grafts. ABO minor MM was associated with an increase in early nonrelapse mortality (NRM) (18% versus 13%; HR, 1.48; 95% CI, 1.06 to 2.06; P = .02). In an independent Center for International Blood and Marrow Transplant Research (CIBMTR) analysis of 435 lymphoma patients receiving mobilized peripheral blood grafts, impairment of OS (HR, 1.55; 95% CI, 1.07 to 2.25; P = .021) and increased NRM (HR, 1.72; 95% CI, 1.11 to 2.68; P = .03) were observed in recipients of ABO minor-MM grafts. A second independent analysis of a CIBMTR data set including 5179 patients with acute myeloid leukemia and myelodysplastic syndrome identified a nonsignificant trend toward decreased OS in recipients of ABO minor-MM grafts and also found ABO major MM to be significantly associated with decreased OS (HR, 1.19; 95% CI, 1.08 to 1.31; P < .001) and increased NRM (HR, 1.23; 95% CI, 1.08 to 1.4; P = .002). ABO minor and major MM are risk factors for worse transplantation outcomes, although the associated hazards may not be uniform across different transplantation populations. Further study is warranted to determine which patient populations are at greatest risk, and whether this risk can be modified by anti-B cell therapy or other peri-transplantation treatments.

Indexed as

ABO Blood-Group SystemHematopoietic Stem Cell TransplantationAdolescentAdultAgedAllograftsChildChild, PreschoolDisease-Free SurvivalFemaleHematologic NeoplasmsHumansInfantMaleMiddle AgedRetrospective StudiesABO Blood-Group SystemABO mismatchAllogeneicNonrelapse mortalityTransplantation

Identifiers

PMID25572032
PMCPMC4363312

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.